Objective To help investors assess and control the costs of new drug development and reduce the risks of new drug development projects.Methods Cost analysis and financial forecasting were carried out with the integrat...Objective To help investors assess and control the costs of new drug development and reduce the risks of new drug development projects.Methods Cost analysis and financial forecasting were carried out with the integrated approach of earned value management.According to the principle of earned value management deviation analysis,the basic process of the new drug research and development project was combined with the hypothesis method from the research of Tufts Drug Development Research Center.Results and Conclusion If the project progress check was carried out in the clinical trial,the project costs were found overspent,the efficiency was low,the project progress was faster,and the resource investment was ahead.It is recommended that the adjustment should be made to reduce the input of resources,and increase the efficient key personnel to take the place of some less efficient staff.展开更多
The Chinese Academy of Science (CAS), the top national research hub for natural sciences, has always been committed itself to the national target of research and development (R&D) of new medicines. During the past...The Chinese Academy of Science (CAS), the top national research hub for natural sciences, has always been committed itself to the national target of research and development (R&D) of new medicines. During the past several decades, a great number of R&D achievements have been attained. During the period from 1986 to 1999, for example, 135 pharmacutical projects won prizes of the CAS awards for natural sciences, inventions and S&T progress (roughly ac-展开更多
Since President Obama announced the Precision Medicine Initiative from a national strategy perspective in his State of the Union address,precision medicine has rapidly become a world-wide hotspot and drawn global atte...Since President Obama announced the Precision Medicine Initiative from a national strategy perspective in his State of the Union address,precision medicine has rapidly become a world-wide hotspot and drawn global attention in the medical field.Precision medicine aims at applying genetic information of individual diseases to guide his or her diagnosis and treatment.展开更多
背景和目的:2016年美国国家癌症研究所(National Cancer Institute,NCI)宣布不再使用NCI-60细胞系进行药物筛选,提示传统的肿瘤细胞系失去作为药物研发和基础研究工具的价值。NCI-60细胞“退休”原因是基于癌症细胞系和动物的实验结果...背景和目的:2016年美国国家癌症研究所(National Cancer Institute,NCI)宣布不再使用NCI-60细胞系进行药物筛选,提示传统的肿瘤细胞系失去作为药物研发和基础研究工具的价值。NCI-60细胞“退休”原因是基于癌症细胞系和动物的实验结果没有在临床试验中获得对应的预期,导致绝大部分潜在药物临床试验失败。癌症细胞系失去价值归因于肿瘤细胞经过长期培养后,其增殖和转移等主要生物学行为和与之有关的关键蛋白质系统发生了根本改变,已不能代表患者的真实癌症特征。现阶段需要创立一种来源于患者新鲜癌症组织和具有清晰临床背景的新癌症模型。本研究旨在为药物研发和基础研究建立经济的患者来源的可以无限传代的乳腺癌原代细胞系。方法:乳腺癌组织在贵州医科大学附属医院乳腺外科收集。肿瘤组织样本收集得到贵州医科大学附属医院伦理委员会批准(伦理编号:2022伦理第313号),收集和使用肿瘤组织均遵守赫尔辛基宣言,患者的乳腺癌组织消化分离后在BCMI培养基中培养,待乳腺癌细胞增殖到一定数量时更换成DMEM培养基。乳腺癌细胞经短串联重复序列(short tandem repeat,STR)检测确定细胞特异性遗传学标志和来源。克隆形成实验和动物实验分析乳腺癌原代细胞系形成肿瘤的能力。结果:成功建立了6种乳腺癌原代细胞系。他们具有清晰的临床病理学特征,包括病理学标志性分子检测、临床诊断、治疗方案和结果以及确定的预后结果。STR检测确定了6种乳腺癌原代细胞系特异性遗传标志和确定了该细胞系的来源。克隆形成实验和动物移植实验说明乳腺癌原代细胞系增殖能力显著大于传统乳腺癌细胞系,二者在形成肿瘤能力方面存在明显的差异。结论:构建的6种乳腺癌原代细胞系为乳腺癌药物研发和基础研究提供了新的癌症模型。展开更多
Objective:To summarize and expound the general situation of precision medicine for cancer according to the current international research hot spots and treatment frontiers of cancer.Methods:This article makes an inven...Objective:To summarize and expound the general situation of precision medicine for cancer according to the current international research hot spots and treatment frontiers of cancer.Methods:This article makes an inventory from five aspects of treatment methods,detection technology,new drug research and development,information data and traditional Chinese medicine,"from point to surface","from outside to inside"and"integration of Chinese and Western medicine",to explore the whole picture of tumor treatment and research.Results:With the rapid development of tumor precision medicine in recent years,the tumor treatment methods have been developed from single to multiple.The research technology has been changed from macro to micro.The therapeutic drugs have been changed from systemic chemotherapy to targeted therapy,immunotherapy and other technologies.The treatment concept has been changed from local to overall.And the integrated treatment methods of traditional Chinese and Western medicine have brought a new chapter to tumor treatment.Conclusion:Through a series of new technologies,new methods and new concepts,tumor precision medicine promotes the treatment of tumors with integrated Chinese and Western medicine into a new chapter.展开更多
As a knowledge-intensive and promising strategic emerging industry, the biomedical industry has high entry thresholds, large R&D investment, long cycle, high risk and high return. In all technical fields, the biom...As a knowledge-intensive and promising strategic emerging industry, the biomedical industry has high entry thresholds, large R&D investment, long cycle, high risk and high return. In all technical fields, the biomedical industry has the highest dependence on intellectual property rights, and the protection of pharmaceutical intellectual property rights by domestic and foreign biomedical enterprises also runs through the whole process of drug research and development. Extending the patent protection period of drugs as well as forming and strengthening patent fortresses requires a patent network that surrounds drugs to maximize the value of intellectual property protection, which is also the focus of every pharmaceutical company with patent rights. By analyzing the patent portfolio of Clovis Oncology Company in the United States on Rucaparib and the patent portfolio of other companies or applicants on Rucaparib, we can have a clearer understanding of the strategy of extending the patent protection period of a new drug product.展开更多
Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the operational research conditions compared to DR-TB patients treate...Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the operational research conditions compared to DR-TB patients treated without bedaquiline in their regimen, and to describe the adverse events that occurred among patients treated with bedaquiline in the Philippines. Design: Patients who were treated with a bedaquiline-containing regimen from June 2016 to May 2017 were included in this study as the intervention group, while patients who were treated without bedaquiline regimen from January 2013 to May 2016 were included as the comparison group. The interim treatment outcomes were compared using Chi-square test. The analysis of time to culture conversion within 6 months of treatment was conducted. A Cox proportional hazard model was constructed to identify the variables associated with a favorable interim treatment outcome. The R program was used for statistical analysis. Results: On the 6th month of treatment, the culture conversion for patients treated with a bedaquiline-containing regimen was significantly higher than with the comparison group [63/75 (84.0%) vs 84/117 (71.8%), p = 0.012)]. Nearly 15% of the patients treated with bedaquiline were lost to follow-up. Frequent adverse events included vomiting, dizziness, nausea, joint pain, and abdominal pain. Conclusion: The patients who were treated with bedaquiline-containing regimen have better interim treatment outcomes than those treated without bedaquiline, but the proportion of patients who were lost to follow-up remains substantial.展开更多
文摘Objective To help investors assess and control the costs of new drug development and reduce the risks of new drug development projects.Methods Cost analysis and financial forecasting were carried out with the integrated approach of earned value management.According to the principle of earned value management deviation analysis,the basic process of the new drug research and development project was combined with the hypothesis method from the research of Tufts Drug Development Research Center.Results and Conclusion If the project progress check was carried out in the clinical trial,the project costs were found overspent,the efficiency was low,the project progress was faster,and the resource investment was ahead.It is recommended that the adjustment should be made to reduce the input of resources,and increase the efficient key personnel to take the place of some less efficient staff.
文摘The Chinese Academy of Science (CAS), the top national research hub for natural sciences, has always been committed itself to the national target of research and development (R&D) of new medicines. During the past several decades, a great number of R&D achievements have been attained. During the period from 1986 to 1999, for example, 135 pharmacutical projects won prizes of the CAS awards for natural sciences, inventions and S&T progress (roughly ac-
文摘Since President Obama announced the Precision Medicine Initiative from a national strategy perspective in his State of the Union address,precision medicine has rapidly become a world-wide hotspot and drawn global attention in the medical field.Precision medicine aims at applying genetic information of individual diseases to guide his or her diagnosis and treatment.
文摘背景和目的:2016年美国国家癌症研究所(National Cancer Institute,NCI)宣布不再使用NCI-60细胞系进行药物筛选,提示传统的肿瘤细胞系失去作为药物研发和基础研究工具的价值。NCI-60细胞“退休”原因是基于癌症细胞系和动物的实验结果没有在临床试验中获得对应的预期,导致绝大部分潜在药物临床试验失败。癌症细胞系失去价值归因于肿瘤细胞经过长期培养后,其增殖和转移等主要生物学行为和与之有关的关键蛋白质系统发生了根本改变,已不能代表患者的真实癌症特征。现阶段需要创立一种来源于患者新鲜癌症组织和具有清晰临床背景的新癌症模型。本研究旨在为药物研发和基础研究建立经济的患者来源的可以无限传代的乳腺癌原代细胞系。方法:乳腺癌组织在贵州医科大学附属医院乳腺外科收集。肿瘤组织样本收集得到贵州医科大学附属医院伦理委员会批准(伦理编号:2022伦理第313号),收集和使用肿瘤组织均遵守赫尔辛基宣言,患者的乳腺癌组织消化分离后在BCMI培养基中培养,待乳腺癌细胞增殖到一定数量时更换成DMEM培养基。乳腺癌细胞经短串联重复序列(short tandem repeat,STR)检测确定细胞特异性遗传学标志和来源。克隆形成实验和动物实验分析乳腺癌原代细胞系形成肿瘤的能力。结果:成功建立了6种乳腺癌原代细胞系。他们具有清晰的临床病理学特征,包括病理学标志性分子检测、临床诊断、治疗方案和结果以及确定的预后结果。STR检测确定了6种乳腺癌原代细胞系特异性遗传标志和确定了该细胞系的来源。克隆形成实验和动物移植实验说明乳腺癌原代细胞系增殖能力显著大于传统乳腺癌细胞系,二者在形成肿瘤能力方面存在明显的差异。结论:构建的6种乳腺癌原代细胞系为乳腺癌药物研发和基础研究提供了新的癌症模型。
基金National Natural Science Foundation of China(No.82174145,81973651)
文摘Objective:To summarize and expound the general situation of precision medicine for cancer according to the current international research hot spots and treatment frontiers of cancer.Methods:This article makes an inventory from five aspects of treatment methods,detection technology,new drug research and development,information data and traditional Chinese medicine,"from point to surface","from outside to inside"and"integration of Chinese and Western medicine",to explore the whole picture of tumor treatment and research.Results:With the rapid development of tumor precision medicine in recent years,the tumor treatment methods have been developed from single to multiple.The research technology has been changed from macro to micro.The therapeutic drugs have been changed from systemic chemotherapy to targeted therapy,immunotherapy and other technologies.The treatment concept has been changed from local to overall.And the integrated treatment methods of traditional Chinese and Western medicine have brought a new chapter to tumor treatment.Conclusion:Through a series of new technologies,new methods and new concepts,tumor precision medicine promotes the treatment of tumors with integrated Chinese and Western medicine into a new chapter.
文摘As a knowledge-intensive and promising strategic emerging industry, the biomedical industry has high entry thresholds, large R&D investment, long cycle, high risk and high return. In all technical fields, the biomedical industry has the highest dependence on intellectual property rights, and the protection of pharmaceutical intellectual property rights by domestic and foreign biomedical enterprises also runs through the whole process of drug research and development. Extending the patent protection period of drugs as well as forming and strengthening patent fortresses requires a patent network that surrounds drugs to maximize the value of intellectual property protection, which is also the focus of every pharmaceutical company with patent rights. By analyzing the patent portfolio of Clovis Oncology Company in the United States on Rucaparib and the patent portfolio of other companies or applicants on Rucaparib, we can have a clearer understanding of the strategy of extending the patent protection period of a new drug product.
文摘Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the operational research conditions compared to DR-TB patients treated without bedaquiline in their regimen, and to describe the adverse events that occurred among patients treated with bedaquiline in the Philippines. Design: Patients who were treated with a bedaquiline-containing regimen from June 2016 to May 2017 were included in this study as the intervention group, while patients who were treated without bedaquiline regimen from January 2013 to May 2016 were included as the comparison group. The interim treatment outcomes were compared using Chi-square test. The analysis of time to culture conversion within 6 months of treatment was conducted. A Cox proportional hazard model was constructed to identify the variables associated with a favorable interim treatment outcome. The R program was used for statistical analysis. Results: On the 6th month of treatment, the culture conversion for patients treated with a bedaquiline-containing regimen was significantly higher than with the comparison group [63/75 (84.0%) vs 84/117 (71.8%), p = 0.012)]. Nearly 15% of the patients treated with bedaquiline were lost to follow-up. Frequent adverse events included vomiting, dizziness, nausea, joint pain, and abdominal pain. Conclusion: The patients who were treated with bedaquiline-containing regimen have better interim treatment outcomes than those treated without bedaquiline, but the proportion of patients who were lost to follow-up remains substantial.
